"Doctor, my wife and I are both carriers of cystic fibrosis. Can we screen for this disease by doing IVF in Georgia?"
This is a common type of consultation I encounter in my overseas reproductive coordination work. When both partners are carriers of an autosomal recessive genetic disease, the risk of having an affected child through natural conception is 25%. For cystic fibrosis (CF), the most common fatal genetic disease among Caucasian populations, preimplantation genetic testing (PGT) is currently the most effective means of阻断.
Direct answer: Yes. Georgia legally offers third-generation IVF technology, including PGT-M (Monogenic) for single-gene disorders. As long as the CFTR gene mutation sites carried by both partners are clearly identified, and the chosen reproductive centre has the genetic laboratory and embryo biopsy capabilities, embryos can be screened to select unaffected ones for transfer.
Why must cystic fibrosis be screened via PGT-M?
Cystic fibrosis is caused by mutations in the CFTR gene, with over 2,000 mutations identified globally, such as the common F508del. If both partners are carriers (heterozygous), each embryo has a 25% chance of being affected, a 50% chance of being a carrier, and only a 25% chance of being completely normal. Conventional prenatal diagnosis (amniocentesis) can only confirm the condition after pregnancy, involving ethical and physical risks of termination. PGT-M completes screening at the embryo stage, preventing the transmission of the genetic disease.
Note: PGT-M can only screen for known mutation sites. If one partner's mutation type is unknown, or if rare mutations are present, genetic testing and family verification must be completed first to design the probes.
PGT screening for cystic fibrosis in Georgia: What do doctors say?
Georgia's assisted reproductive laws do not strictly restrict PGT, allowing for both chromosomal aneuploidy (PGT-A) and monogenic (PGT-M) testing on embryos. However, the technical capabilities of laboratories vary between reproductive centres. From a clinical perspective, centres with independent genetic laboratories can typically perform PGT-M for CF, with a testing cycle of about 2-4 weeks (depending on the number of embryos and the speed of genetic analysis after biopsy). Doctors will require couples to provide previous genetic test reports or undergo retesting at the centre to confirm mutations.
Key tip: Not all clinics in Georgia have PGT-M capabilities. Some centres only offer PGT-A (chromosomal screening) or need to send biopsy samples to laboratories in other European countries. This outsourcing increases time (potentially 1-2 weeks more) and transport risks, plus additional international logistics costs. Before choosing, ask the centre directly if it has PGT-M testing capability for the CFTR gene and whether the testing is done in its own laboratory.
Who is suitable for PGT-M for CF in Georgia? Who is not?
Suitable candidates
- Both partners are CF carriers with clearly identified gene mutation sites.
- One partner is a CF patient, the other is a carrier (the risk of an affected child is 50%, making PGT-M even more necessary).
- History of having a child with CF, wishing to avoid transmission in a subsequent pregnancy.
- Meets basic IVF conditions regarding age, ovarian function, etc., and accepts the potential risks of embryo biopsy.
Unsuitable candidates
- Mutation sites completely unknown and unwilling to undergo genetic testing.
- Female with very poor ovarian reserve (e.g., AMH < 0.5 ng/mL), potentially unable to obtain enough embryos for biopsy.
- Presence of contraindications for PGT, such as severe endometrial pathology or uncontrolled systemic diseases.
- Unable to afford the additional cost of PGT-M (usually $3,000-$6,000 more than conventional IVF).
What is the specific process? What needs to be prepared?
The entire process is divided into three stages: genetic confirmation → ovarian stimulation and embryo culture → PGT-M testing and transfer.
| Step | Content | Time Required |
|---|---|---|
| 1. Genetic counselling & testing | Both partners complete CFTR gene full sequencing or testing for known mutation sites; the Georgian reproductive centre requires reports from a domestic top-tier hospital or its own centre. | 1-2 weeks (skip if already done domestically) |
| 2. Ovarian stimulation & egg retrieval | Standard IVF process: start stimulation on day 2-3 of menstruation, average 10-12 days, then egg retrieval. | About 2 weeks |
| 3. Intracytoplasmic sperm injection (ICSI) | All PGT cycles require ICSI to avoid sperm DNA contamination of the embryo. | 1 day |
| 4. Embryo culture to day 5-6 | Culture to blastocyst stage. | 5-6 days |
| 5. Embryo biopsy | Take 3-5 cells from the trophectoderm of the blastocyst for testing. | 1 day |
| 6. PGT-M testing | Use PCR or NGS technology to detect CFTR mutation sites; PGT-A (chromosomal number screening) can be added simultaneously. | 7-14 days (in-house) or 14-21 days (outsourced) |
| 7. Frozen embryo transfer | Select normal embryos, thaw and transfer. If endometrial preparation is needed, an additional 1-2 weeks may be required. | Depends on endometrial protocol |
Required documents: ID cards and passports (valid for at least 6 months) for both partners, marriage certificate (needs translation notarisation or local acceptance), previous genetic test reports, previous fertility history medical records, infectious disease screening reports (HIV, hepatitis B, syphilis, etc., valid within 6 months).
Easily overlooked details
- Mutation type needs precise classification: The CFTR gene has many intronic and rare mutations that routine testing methods might miss. Consider whole exome sequencing or a dedicated CF panel.
- Probe design time: If the couple's mutation types are rare, the centre needs custom PGT probes, which can take an additional 2-4 weeks. Confirm probe readiness before starting the cycle.
- Impact of biopsy on embryos: The freeze-thaw survival rate after biopsy of good-quality blastocysts is about 95%, but 3-5% of embryos may not survive the biopsy. Be mentally prepared.
- PGT-M results are not 100% accurate: Due to technical limitations (e.g., allele drop-out ADO) or mosaicism, there is a misdiagnosis rate of about 0.1-1%. Prenatal diagnosis (amniocentesis) after transfer is still recommended for confirmation.
Common pitfalls
1. Assuming all IVF centres in Georgia offer PGT-M. In reality, some small clinics only do PGT-A or even just morphological assessment. Get written proof before signing a contract that the centre has PGT-M capability and can cover CFTR gene mutations.
2. Ignoring the timeliness of the couple's genetic reports. Some domestic hospital reports only state "heterozygous mutation" without specific base changes, making them unusable for probe design. Retesting or supplementary reports are needed.
3. Overly trusting "guaranteed success" promises. PGT-M only screens for normal embryos; it does not guarantee implantation or live birth. Embryo quality, uterine receptivity, and age are variables. Be wary of any centre claiming 100% success.
4. Ignoring the risk of insufficient embryo numbers. If only 2-3 blastocysts are obtained in one cycle, they might all be abnormal or carriers after biopsy, leaving no embryos for transfer. Assess ovarian reserve before deciding to start.
Cost factors
In Georgia, the total cost for one cycle of conventional IVF + PGT-M is approximately $12,000-$20,000 (RMB 85,000-140,000), depending on:
- Biopsy and testing fees (PGT-M is usually charged separately, about $3,000-$5,000; adding PGT-A costs an extra $1,500-$3,000).
- Whether the lab work is outsourced (higher cost and longer cycle).
- Type of ovarian stimulation medication (imported drugs are 30-50% more expensive than domestic ones).
- Whether multiple stimulation cycles are needed to accumulate embryos.
Frequently asked questions
- Q: My wife and I are both CF carriers, but we don't know the specific mutation sites. Can we get tested in Georgia first?
A: Yes. Some centres in Georgia collaborate with genetic labs and can do CFTR full gene sequencing via blood test, costing about $500-$1,000. However, it's recommended to do this in a domestic top-tier hospital for lower cost and mutual recognition of results. - Q: Does PGT-M damage the embryo? Can it cause birth defects?
A: The biopsy takes cells from the trophectoderm, which will become the placenta, not the inner cell mass (which becomes the fetus). Large-scale studies have not found a significant increase in newborn malformation rates due to biopsy. - Q: What if PGT-M shows all embryos carry the CF mutation?
A: Carrier embryos (heterozygous) are not affected and can be transferred. However, the child should be informed about genetic counselling for future reproduction. Affected embryos (homozygous) are not recommended for transfer. - Q: Do I need a visa for IVF in Georgia? How long does it take?
A: Chinese citizens need an e-visa or sticker visa for Georgia, usually taking 5-10 working days. Prepare at least one month in advance.
Practitioner's observations and reminders
As a practitioner with nearly 8 years of experience in the assisted reproduction field in Georgia, I observe that most families coming here for CF genetic screening do so because of long waiting times for third-generation IVF in China, policy restrictions (e.g., requiring a history of genetic disease childbirth), or high costs. The process in Georgia is relatively quick (about 2-3 months from starting the cycle to transfer), and the law does not strictly prohibit PGT. However, it must be emphasised: The success of PGT-M depends on having a sufficient number of blastocysts. If the female partner is over 38 years old with AMH below 1.0 ng/mL, consider 1-2 cycles of egg/embryo freezing accumulation before a single biopsy screening.
Additionally, English proficiency in Georgia's medical environment is acceptable, but some junior staff only speak Russian or Georgian. It is advisable to choose a centre with a Chinese coordinator to minimise communication errors.
Suggestions for next steps
If you and your partner plan to go to Georgia for PGT screening for cystic fibrosis, follow this order:
- Complete comprehensive reproductive genetic counselling in China, obtaining CFTR gene test reports for both partners (clearly stating mutation sites and inheritance pattern).
- Assess the female partner's ovarian function (AMH, antral follicle count, baseline hormone profile) to determine suitability for stimulation.
- Contact Georgian reproductive centres to confirm their PGT-M lab can test your specific mutations, and understand the specific biopsy, testing cycle, and costs.
- Book travel, apply for a visa, and prepare all documents (passports valid >6 months, notarised marriage certificate).
- Complete necessary infectious disease screening and routine health checks (reports valid within 6 months) before departure.
Risk reminder: No assisted reproductive technology can completely avoid the transmission of genetic diseases (including the very low false-negative rate of PGT-M, embryo mosaicism, de novo mutations, etc.). Prenatal diagnosis (chorionic villus sampling or amniocentesis) after transfer is essential to ultimately confirm the fetal genotype. Also, pay attention to the qualifications of medical institutions in Georgia – prioritise centres with international accreditation (e.g., JCI, ISO) or registration with local health authorities.
Comments (0)